Clinical Trial Goal
To find out if the combination of pirtobrutinib, rituximab and venetoclax is safe and works well to treat MCL that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have MCL that has not yet been treated
- Have cancer cells that have marker CD20 (CD20+). Your doctor can tell you this
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Pirtobrutinib is a small molecule inhibitor that blocks BTK in certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get:
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get:
- Pirtobrutinib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Rituximab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Venetoclax– A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved pirtobrutinib to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), rituximab to treat MCL and venetoclax to treat CLL or SLL. Using them in this combination to treat MCL that has not yet been treated, is new and unproven.
Locations
Mayo Clinic in RochesterRECRUITING
Rochester, Minnesota
Yucai Wang, MD, 507-284-2511, Wang.Yucai@mayo.edu
MD Anderson Cancer CenterRECRUITING
Houston, Texas
Michael Wang, MD, MS, 713-792-2860, miwang@mdanderson.org
Sponsors
collaborator: Eli Lilly and Company, collaborator: Genentech, Inc., collaborator: AbbVie, lead: M.D. Anderson Cancer Center
